The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLVI.f

Hemolytic and uremic syndrome (HUS). See also under Xaf

Publications

Nishijima Y, Hirata H, Himeno A, Kida H, Matsumoto M, Takahashi R, Otani Y, Inoue K, Nagatomo I, Takeda Y, Kijima T, Tachibana I, Fujimura Y, Kumanogoh A

Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.

Internal medicine (Tokyo, Japan) 2013;52;1111-4 — 2013 — 1111-4

van der Heijden M, Ackland SP, Deveridge S

Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy--a case report and review of the literature.

Acta oncologica (Stockholm, Sweden) 1998;37;107-9 — 1998 — 107-9

van der Lelie H, Baars JW, Rodenhuis S, van Dijk MA, de Glas-Vos CW, Thomas BL, van Oers RH, von dem Borne AE

Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.

Cancer 1995 Dec 01;76;2338-42 — 1995 Dec 01 — 2338-42